Literature DB >> 20860602

Involvement of M2-polarized macrophages in the ascites from advanced epithelial ovarian carcinoma in tumor progression via Stat3 activation.

Kiyomi Takaishi1, Yoshihiro Komohara, Hironori Tashiro, Hideyuki Ohtake, Takenobu Nakagawa, Hidetaka Katabuchi, Motohiro Takeya.   

Abstract

Ascites macrophages in advanced epithelial ovarian cancer (AdEOC) are involved in cancer metastasis and progression by modifying the tumor microenvironment. However, the precise mechanisms of cell-to-cell interaction between macrophages and tumor cells are still unclear. This study focused on the activation of signal transducer and activator of transcription 3 (Stat3) which is a critical signal transduction molecule at a point of convergence for numerous oncogenic signaling pathways as well as controlling the M2-poralization of macrophages. AdEOC ascites, in which high concentration of interleukin (IL)-6, IL-10, growth-related oncogene-alpha and vascular endothelial growth factor were detected, stimulated the proliferation of SKOV3 cells, a human ovarian cancer cell line. The simultaneous blocking of IL-6 and IL-10 by neutralizing antibodies suppressed ascites-induced tumor cell proliferation. Stat3 activation in SKOV3 cells was induced by co-culture with macrophages especially with macrophage colony stimulating factor-primed M2 macrophages but lesser extent with granulocyte-macrophage colony stimulating factor-primed immature macrophages. Cyclin-D1 expression in SKOV3 cells was also significantly induced by co-culture with macrophages. Blocking of Stat3 in macrophages by small interfering RNA inhibited the production of IL-6 and IL-10 by macrophages, and suppressed Stat3 activation and cyclin-D1 induction in co-cultured SKOV3 cells. Stat3 activation in SKOV3 cells was abrogated by simultaneous neutralization of IL-6 and IL-10. These results indicate that Stat3 activation by IL-6 and IL-10 plays an important role in cell-to-cell interaction between tumor cells and macrophages in the ascites of AdEOC.
© 2010 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20860602     DOI: 10.1111/j.1349-7006.2010.01652.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  65 in total

1.  Fractalkine receptor CX(3)CR1 is expressed in epithelial ovarian carcinoma cells and required for motility and adhesion to peritoneal mesothelial cells.

Authors:  Mijung Kim; Lisa Rooper; Jia Xie; Andre A Kajdacsy-Balla; Maria V Barbolina
Journal:  Mol Cancer Res       Date:  2011-11-07       Impact factor: 5.852

2.  Macrophage Blockade Using CSF1R Inhibitors Reverses the Vascular Leakage Underlying Malignant Ascites in Late-Stage Epithelial Ovarian Cancer.

Authors:  Diana L Moughon; Huanhuan He; Shiruyeh Schokrpur; Ziyue Karen Jiang; Madeeha Yaqoob; John David; Crystal Lin; M Luisa Iruela-Arispe; Oliver Dorigo; Lily Wu
Journal:  Cancer Res       Date:  2015-10-15       Impact factor: 12.701

3.  The combination of a novel immunomodulator with a regulatory T cell suppressing antibody (DTA-1) regress advanced stage B16F10 solid tumor by repolarizing tumor associated macrophages in situ.

Authors:  Sayantan Banerjee; Kuntal Halder; Sweta Ghosh; Anamika Bose; Subrata Majumdar
Journal:  Oncoimmunology       Date:  2015-01-30       Impact factor: 8.110

4.  Imaging of Tumor-Associated Macrophages in a Transgenic Mouse Model of Orthotopic Ovarian Cancer.

Authors:  Huanhuan He; Alan C Chiu; Masamitsu Kanada; Bruce T Schaar; Venkatesh Krishnan; Christopher H Contag; Oliver Dorigo
Journal:  Mol Imaging Biol       Date:  2017-10       Impact factor: 3.488

5.  Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway.

Authors:  Xiang Li; Shaomin Wang; Wei Mu; Jennifer Barry; Anna Han; Richard L Carpenter; Bing-Hua Jiang; Stephen C Peiper; Mỹ G Mahoney; Andrew E Aplin; Hong Ren; Jun He
Journal:  J Exp Clin Cancer Res       Date:  2022-01-27

6.  Tumor-associated macrophages are involved in tumor progression in papillary renal cell carcinoma.

Authors:  Carl Ludwig Behnes; Felix Bremmer; Bernhard Hemmerlein; Arne Strauss; Philipp Ströbel; Heinz-Joachim Radzun
Journal:  Virchows Arch       Date:  2013-12-11       Impact factor: 4.064

7.  Computational modeling of malignant ascites reveals CCL5-SDC4 interaction in the immune microenvironment of ovarian cancer.

Authors:  Soochi Kim; Youngjin Han; Se Ik Kim; Juwon Lee; HyunA Jo; Wenyu Wang; Untack Cho; Woong-Yang Park; Thomas A Rando; Danny N Dhanasekaran; Yong Sang Song
Journal:  Mol Carcinog       Date:  2021-03-15       Impact factor: 4.784

8.  Clinical significance of side population in ovarian cancer cells.

Authors:  Shinji Hosonuma; Yoichi Kobayashi; Satoshi Kojo; Haruka Wada; Ken-ichiro Seino; Kazushige Kiguchi; Bunpei Ishizuka
Journal:  Hum Cell       Date:  2011-01-07       Impact factor: 4.174

9.  The expression of p-STAT3 in stage IV melanoma: risk of CNS metastasis and survival.

Authors:  Ian Lee; Patricia S Fox; Sherise D Ferguson; Roland Bassett; Ling-Yuan Kong; Christopher W Schacherer; Jeffrey E Gershenwald; Elizabeth A Grimm; Gregory N Fuller; Amy B Heimberger
Journal:  Oncotarget       Date:  2012-03

Review 10.  Specialized immune responses in the peritoneal cavity and omentum.

Authors:  Mingyong Liu; Aaron Silva-Sanchez; Troy D Randall; Selene Meza-Perez
Journal:  J Leukoc Biol       Date:  2020-09-02       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.